Eli Lilly Loxo Oncology Transaction Clears A Hurdle

Eli Lilly Loxo Oncology Transaction Clears A Hurdle

Source: 
CP Wire
snippet: 

Eli Lilly and Company (NYSE: LLY) (“Lilly”) and Loxo Oncology, Inc. (NASDAQ: LOXO) (“Loxo Oncology”) announcedon 2/1/19 the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), in connection with Lilly’s previously-announced tender offer to acquire all outstanding shares of Loxo Oncology for a purchase price of $235.00 per share in cash (the “Offer Price”), or approximately $8.0 billion.